Find out what you know about which diabetes drugs in which classes show CV protective properties and results of the trials that support their use.
Obstructive Sleep Apnea and Hypertension Update: FDA Clears Phase 2 Trial of Lorundrostat, an Oral Aldosterone Synthase Inhibitor
Mineralys Therapeutics also expects topline data from its phase 2 study of lorundrostat for the treatment of uncontrolled hypertension or resistant hypertension when used as an add-on therapy.
Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care
Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.
Mobile App Shows Promise for Hypertension Management: Daily Dose
Your daily dose of the clinical news you may have missed.
Obesity & Type 2 Diabetes: An Expert Discussion
In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.
Smartphone App Shows Promise for Managing Hypertension in Observational Study
People with hypertension who adhered to the mobile app demonstrated well-controlled blood pressure over a 12-week observational period.
More than Half of US Adults Eligible for Semaglutide: Daily Dose